stockrow
Friday 6 November 2026
Export PROF’s income statement to Excel — free account
Profound Medical
PROF Healthcare Medical Devices
Profound Medical’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, up 50.7% from fiscal 2024.
- Revenue
- +85.9%
- EPS
- +18.8%
- Free cash flow
- +47.9%
- Total debt
- +0.71%
Quarter to September 2026, against a year earlier
7.12
0.24
+3.49%
Follow PROF
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
8.97 | 12.86 | 12.50 | 14.78 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(42.35) | (21.64) | (27.40) | (36.24) | |
P/B ratio |
4.99 | 4.93 | 3.96 | 3.58 | |
Price to Tangible BV |
5.00 | 4.94 | 3.97 | 3.59 | |
EV/Sales |
7.94 | 11.32 | 10.31 | 11.63 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.96) | (5.99) | (5.04) | (4.90) | |
EV/FCF |
(5.84) | (5.88) | (4.95) | (4.82) | |
Quick Ratio |
3.67 | 5.25 | 5.63 | 11.02 | |
Current Ratio |
4.54 | 6.46 | 6.56 | 12.52 | |
Net Debt/EBITDA |
3.75 | 3.09 | 5.78 | 7.61 | |
Debt/Assets |
7.76% | 7.22% | 6.13% | 5.81% | |
Debt/Equity |
0.11 | 0.09 | 0.08 | 0.07 | |
Asset Turnover |
0.47 | 0.34 | 0.28 | 0.22 | |
Operating CF/Net income |
0.65 | 1.19 | 1.22 | 0.80 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (2.22) | |
Research and Development Expense of Revenue |
59.06% | 227.71% | 98.59% | 71.47% | |
Selling, General and Administrative Expense of Revenue |
98.63% | 296.38% | 123.50% | 118.59% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2.61% | 35.20% | 19.64% | 23.11% | |
Graham Net Nets |
0.18 | 0.19 | 0.24 | 0.27 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(16.06%) | (14.52%) | (19.14%) | (17.92%) | |
Free Cash Flow Yield |
(15.16%) | (14.98%) | (16.65%) | (16.33%) | |
Revenue per Share |
0.27 | 0.07 | 0.15 | 0.20 | |
Operating CF per Share |
(0.14) | (0.31) | (0.24) | (0.22) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.14) | (0.31) | (0.24) | (0.23) | |
Cash per Share |
0.91 | 1.05 | 1.39 | 1.98 | |
Shareholders Equity per Share |
1.16 | 1.37 | 1.64 | 2.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.16 | 1.37 | 1.64 | 2.20 | |
Free Cash Flow |
(5.01) | (11.34) | (8.58) | (6.81) | |
Working Capital |
42.77 | 49.75 | 58.92 | 70.01 | |
Capital Expenditures |
— | — | — | (0.24) | |
Net Current Asset Value |
39.19 | 46.29 | 55.50 | 65.05 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.58 | 7.26 | 7.69 | 7.12 | |
Average Payables |
0.88 | 0.95 | 1.60 | 1.44 | |
Average Inventory |
9.29 | 9.40 | 7.90 | 7.02 | |
Average Assets |
50.23 | 56.03 | 67.16 | 73.85 | |
Average Common Equity |
37.33 | 44.53 | 55.11 | 63.43 |
Columns are period end dates · fundamentals updated 5 Nov 2026